DK1075276T3 - Adjuvanssammensætning og fremgangsmåder til dens anvendelse - Google Patents

Adjuvanssammensætning og fremgangsmåder til dens anvendelse

Info

Publication number: DK1075276T3
Authority: DK; Denmark
Prior art keywords: volume; emulsion; weight; stable; preferred
Prior art date: 1998-05-07

Application number

DK99922832T

Other languages

English (en)

Inventor

Glen D Leesman

Original Assignee

Corixa Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-07

Filing date

1999-05-07

Publication date

2008-02-11

1999-05-07 Application filed by Corixa Corp filed Critical Corixa Corp

2008-02-11 Application granted granted Critical

2008-02-11 Publication of DK1075276T3 publication Critical patent/DK1075276T3/da

Links

239000000203 mixture Substances 0.000 title abstract 3
239000002671 adjuvant Substances 0.000 title abstract 2
239000000839 emulsion Substances 0.000 abstract 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
229940035032 monophosphoryl lipid a Drugs 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
229940087168 alpha tocopherol Drugs 0.000 abstract 1
239000003963 antioxidant agent Substances 0.000 abstract 1
230000003078 antioxidant effect Effects 0.000 abstract 1
235000006708 antioxidants Nutrition 0.000 abstract 1
230000002238 attenuated effect Effects 0.000 abstract 1
229920001400 block copolymer Polymers 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
239000007764 o/w emulsion Substances 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
229920001993 poloxamer 188 Polymers 0.000 abstract 1
229940031439 squalene Drugs 0.000 abstract 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
229960000984 tocofersolan Drugs 0.000 abstract 1
239000002076 α-tocopherol Substances 0.000 abstract 1
235000004835 α-tocopherol Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Biological Depolymerization Polymers (AREA)

DK99922832T 1998-05-07 1999-05-07 Adjuvanssammensætning og fremgangsmåder til dens anvendelse DK1075276T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8467898P	1998-05-07	1998-05-07
PCT/US1999/009978 WO1999056776A2 (en)	1998-05-07	1999-05-07	Adjuvant composition and methods for its use

Publications (1)

Publication Number	Publication Date
DK1075276T3 true DK1075276T3 (da)	2008-02-11

Family

ID=22186530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99922832T DK1075276T3 (da)	1998-05-07	1999-05-07	Adjuvanssammensætning og fremgangsmåder til dens anvendelse

Country Status (20)

Country	Link
US (2)	US6630161B1 (da)
EP (1)	EP1075276B1 (da)
JP (1)	JP2002513773A (da)
KR (1)	KR100682154B1 (da)
CN (2)	CN101219217A (da)
AT (1)	ATE375803T1 (da)
AU (1)	AU755445B2 (da)
BR (1)	BR9910269A (da)
CA (1)	CA2330610A1 (da)
CY (1)	CY1107265T1 (da)
DE (1)	DE69937343T2 (da)
DK (1)	DK1075276T3 (da)
ES (1)	ES2296390T3 (da)
HK (1)	HK1039072A1 (da)
HU (1)	HU225844B1 (da)
NO (1)	NO20005596L (da)
NZ (1)	NZ508013A (da)
PT (1)	PT1075276E (da)
WO (1)	WO1999056776A2 (da)
ZA (1)	ZA200006379B (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6491919B2 (en)	1997-04-01	2002-12-10	Corixa Corporation	Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
HK1039072A1 (zh) *	1998-05-07	2002-04-12	科里克萨有限公司	佐剂组合物及其使用方法
DE19859045A1 (de) *	1998-12-21	2000-06-29	Fresenius Pharma Austria Gmbh	Emulsion vom Typ Öl in Wasser mit Schutzwirkung gegen Peroxidationsschäden an menschlichen Organen, deren Herstellung und Verwendung
US6835721B2 (en)	1999-02-01	2004-12-28	Eisai Co., Ltd.	Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) *	1999-02-01	2011-03-29	Eisai R & D Management Co., Ltd.	Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) *	1999-02-01	2004-01-08	Hawkins Lynn D.	Immunomodulatory compounds and method of use thereof
US20030031684A1 (en)	2001-03-30	2003-02-13	Corixa Corporation	Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
PT1606261E (pt)	2003-03-10	2010-01-11	Nycomed Gmbh	Novo processo para a preparação de roflumilast
SI1651265T1 (sl) *	2003-07-24	2008-10-31	Merial Ltd	Formulacije cepiva, ki obsegajo emulzijo olje v vodi
ZA200700457B (en) *	2004-06-15	2008-08-27	New York Blood Ct Inc	Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
FR2873386B1 (fr)	2004-07-22	2011-01-14	Agence Francaise De Securite Sanitaire Des Aliments Afssa	Composition vaccinale contre le rhodococcus equi
DE102004046235A1 (de) *	2004-09-22	2006-03-30	Altana Pharma Ag	Arzneimittelzubereitung
CN1320924C (zh) *	2005-01-07	2007-06-13	邢为藩	一种自乳化疫苗佐剂及其制备方法
US8663694B2 (en)	2005-03-16	2014-03-04	Takeda Gmbh	Taste masked dosage form containing roflumilast
PT1861120T (pt)	2005-03-23	2016-08-18	Glaxosmithkline Biologicals Sa	Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
US20070292418A1 (en) *	2005-04-26	2007-12-20	Eisai Co., Ltd.	Compositions and methods for immunotherapy
EP1874342B1 (en)	2005-04-26	2018-06-06	Eisai R&D Management Co., Ltd.	Compositions and methods for cancer immunotherapy
US20090304742A1 (en)	2005-11-04	2009-12-10	Novartis Vaccines And Diagnostics Srl	Influenza vaccines with reduced amount of emulsion adjuvant
WO2007052061A2 (en)	2005-11-04	2007-05-10	Novartis Vaccines And Diagnostics Srl	Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
EP1951298A1 (en)	2005-11-04	2008-08-06	Novartis Vaccines and Diagnostics S.r.l.	Adjuvanted influenza vaccines including cytokine-inducing agents
ES2420829T3 (es)	2005-11-04	2013-08-27	Novartis Vaccines And Diagnostics S.R.L.	Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
US7848801B2 (en)	2005-12-30	2010-12-07	Tti Ellebeau, Inc.	Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
EP3753574A1 (en)	2006-01-27	2020-12-23	Seqirus UK Limited	Influenza vaccines containing hemagglutinin and matrix proteins
CA2646539A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Imidazoquinoxaline compounds as immunomodulators
WO2007109810A2 (en) *	2006-03-23	2007-09-27	Novartis Ag	Methods for the preparation of imidazole-containing compounds
CA2646891A1 (en) *	2006-03-23	2007-09-27	Novartis Ag	Immunopotentiating compounds
EP2004226A1 (en)	2006-03-24	2008-12-24	Novartis Vaccines and Diagnostics GmbH & Co. KG	Storage of influenza vaccines without refrigeration
DK2054431T3 (da)	2006-06-09	2012-01-02	Novartis Ag	Konformere af bakterielle adhæsiner
HRP20140488T1 (hr)	2006-07-17	2014-07-04	Glaxosmithkline Biologicals S.A.	Cjepivo protiv influence
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
ES2536401T3 (es)	2006-09-11	2015-05-25	Novartis Ag	Fabricación de vacunas contra virus de la gripe sin usar huevos
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
PT2468300T (pt)	2006-09-26	2018-01-30	Infectious Disease Res Inst	Composição para vacina contendo adjuvante sintético
SG177141A1 (en)	2006-12-06	2012-01-30	Novartis Ag	Vaccines including antigen from four strains of influenza virus
EP2123259A1 (en) *	2007-01-16	2009-11-25	Hokkaido University	Liposome preparation for iontophoresis having antioxidant component encapsulated therein
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
EA201070066A1 (ru)	2007-06-27	2010-06-30	Новартис Аг	Вакцины против гриппа с низким содержанием добавок
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
EP2173376B1 (en)	2007-08-02	2015-03-25	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope influenza vaccines
CA2700808C (en)	2007-09-27	2017-11-14	Immunovaccine Technologies Inc.	Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) *	2007-10-03	2010-08-19	Immunovaccine Technologies, Inc	Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009115917A2 (en)	2008-03-18	2009-09-24	Novartis Ag	Improvements in preparation of influenza virus vaccine antigens
ES2524699T3 (es)	2008-06-05	2014-12-11	Immunovaccine Technologies Inc.	Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US20110236470A1 (en)	2008-12-03	2011-09-29	Yaffa Mizrachi Nebenzahl	GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
SI2396030T1 (sl)	2009-02-10	2015-12-31	Novartis Ag	Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo
AU2010212548A1 (en)	2009-02-10	2011-09-15	Novartis Ag	Influenza vaccines with increased amounts of H3 antigen
WO2010092479A2 (en)	2009-02-10	2010-08-19	Novartis Ag	Influenza vaccines with reduced amounts of squalene
CA2754618A1 (en)	2009-03-06	2010-09-10	Novartis Ag	Chlamydia antigens
MX2011010735A (es)	2009-04-14	2012-01-25	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
CN102481312B (zh)	2009-06-05	2015-07-15	传染性疾病研究院	合成的吡喃葡萄糖脂佐剂
GB0910046D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB0910045D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
WO2011004263A2 (en)	2009-07-07	2011-01-13	Novartis Ag	Conserved escherichia coli immunogens
PL2464658T3 (pl)	2009-07-16	2015-03-31	Novartis Ag	Immunogeny z Escherichia coli o zniesionej toksyczności
UA107940C2 (en)	2009-09-10	2015-03-10	Merial Ltd	The vaccine composition that includes the saponin-containing adjuvant
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
AR074485A1 (es) *	2009-12-04	2011-01-19	Consejo Nac Invest Cient Tec	Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP5781542B2 (ja)	2009-12-30	2015-09-24	ノバルティスアーゲー	Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
US20110305748A1 (en)	2010-03-11	2011-12-15	Immune Design, Corp.	Vaccines for Pandemic Influenza
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
CA2803239A1 (en)	2010-06-25	2011-12-29	Novartis Ag	Combinations of meningococcal factor h binding proteins
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012117377A1 (en)	2011-03-02	2012-09-07	Novartis Ag	Combination vaccines with lower doses of antigen and/or adjuvant
WO2012141984A1 (en)	2011-04-08	2012-10-18	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
JP6240077B2 (ja)	2011-10-06	2017-11-29	イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅＴｅｃｈｎｏｌｏｇｉｅｓＩｎｃ．	Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
CA2852857A1 (en)	2011-10-20	2013-04-25	Novartis Ag	Adjuvanted influenza b virus vaccines for pediatric priming
WO2013092985A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Stable compositions for immunising against staphylococcus aureus
PL2811981T3 (pl) *	2012-02-07	2019-09-30	Infectious Disease Research Institute	Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
MX372965B (es)	2012-03-08	2020-04-01	Glaxosmithkline Biologicals Sa	Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EP2833900B1 (en)	2012-04-01	2018-09-19	Technion Research & Development Foundation Limited	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
US9241988B2 (en) *	2012-04-12	2016-01-26	Avanti Polar Lipids, Inc.	Disaccharide synthetic lipid compounds and uses thereof
KR102136433B1 (ko)	2012-05-16	2020-07-22	이뮨 디자인 코포레이션	Hsv-2 백신
GB201212010D0 (en) *	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
HUE044211T2 (hu)	2012-08-31	2019-10-28	Glaxosmithkline Biologicals Sa	Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
CN104582723A (zh)	2012-08-31	2015-04-29	诺华股份有限公司	用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
US9526776B2 (en)	2012-09-06	2016-12-27	Glaxosmithkline Biologicals Sa	Combination vaccines with serogroup B meningococcus and D/T/P
WO2014053521A2 (en)	2012-10-02	2014-04-10	Novartis Ag	Nonlinear saccharide conjugates
GB201218195D0 (en)	2012-10-10	2012-11-21	Istituto Zooprofilattico Sperimentale Delle Venezie	Composition
US20150273036A1 (en)	2012-10-12	2015-10-01	Glaxosmithkline Biologicals Sa	Non-cross-linked acellular pertussis antigens for use in combination vaccines
RS56886B1 (sr)	2012-11-30	2018-04-30	Glaxosmithkline Biologicals Sa	Antigeni pseudomonasa i kombinacije antigena
EP2934574A1 (en)	2012-12-18	2015-10-28	GlaxoSmithKline Biologicals SA	Conjugates for protecting against diphtheria and/or tetanus
EP2976107B1 (en) *	2013-03-19	2019-02-20	ASIT BioTech s.a.	Allergen preparation
EP2986303B1 (en)	2013-04-18	2020-02-26	Immune Design Corp.	Gla monotherapy for use in cancer treatment
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
US20150086592A1 (en)	2013-09-25	2015-03-26	Sequoia Sciences, Inc	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US10426828B2 (en)	2014-04-03	2019-10-01	Biondvax Pharmaceuticals Ltd.	Compositions of multimeric-multiepitope influenza polypeptides and their production
EP3270962A4 (en) *	2015-03-17	2018-08-22	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3069729A1 (en)	2015-03-17	2016-09-21	Sequoia Sciences, Inc.	Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
HK1254344A1 (zh)	2015-06-26	2019-07-19	Seqirus UK Limited	抗原匹配的流感疫苗
HUE051783T2 (hu)	2015-07-07	2021-03-29	Seqirus Uk Ltd	Eljárás immunogén hemagglutinin mennyiségi meghatározására
KR101996538B1 (ko) *	2017-02-13	2019-07-04	단디바이오사이언스 주식회사	이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
CN107397956A (zh) *	2017-08-08	2017-11-28	南开大学	一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用
US20210340185A1 (en)	2018-08-29	2021-11-04	Centre Hospitalier Universitaire Vaudois	Ebola vaccine compositions and methods of using same
CN113194986A (zh) *	2018-12-26	2021-07-30	大日本住友制药株式会社	包括疫苗佐剂的制剂
JP2023502650A (ja)	2019-11-18	2023-01-25	セキラスピーティーワイリミテッド	遺伝子再集合インフルエンザウイルスを産生するための方法
CN115300490B (zh) *	2021-05-07	2024-04-16	安徽远望乐桓药业有限公司	包含角鲨烯和甘露醇的药物组合物及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4258029A (en) *	1979-04-23	1981-03-24	Connaught Laboratories Limited	Synthetic adjuvants for stimulation of antigenic responses
ES502788A0 (es) *	1981-06-04	1982-04-01	Landerlan Sa Lab	Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
US4436727A (en) *	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4857318A (en) *	1983-11-07	1989-08-15	Syntex (U.S.A.) Inc.	Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US5656620A (en) *	1984-01-28	1997-08-12	Ismail; Roshdy	Method for treating pain
US5026557A (en) *	1987-09-09	1991-06-25	The Liposome Company, Inc.	Adjuvant composition
US5376369A (en) *	1987-11-03	1994-12-27	Syntex (U.S.A.) Inc.	Vaccine adjuvant
JPS63152327A (ja) *	1987-11-20	1988-06-24	Toyama Chem Co Ltd	脂肪乳剤から成る溶血防止用組成物を含有する製剤
EP0324455A3 (en) *	1988-01-15	1991-03-27	Hans O. Ribi	Novel polymeric immunological adjuvants
HU198843B (en) *	1988-02-08	1989-12-28	Frigyes Kovacs	Process for producing veterinary compositions with disinfecting and antiinflammatory action, comprising natural active ingredient and suitable particularly for treating mastitis
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
JPH02152931A (ja) *	1988-12-02	1990-06-12	Green Cross Corp:The	Ｂ型肝炎ワクチン
US5171737A (en) *	1989-03-03	1992-12-15	The Liposome Company, Inc.	Emulsions
US5858769A (en) *	1989-05-15	1999-01-12	Akzo Nobel N.V.	Device for detecting microorganisms
HU212924B (en) *	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) *	1989-07-03	1991-10-25	Seppic Sa	Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
DE4019062A1 (de) *	1989-08-30	1991-03-07	Kali Chemie Ag	Stabilisierung von perfluorcarbonemulsionen und als emulsionsstabilisierende zusaetze verwendbare perfluorierte heterocyclische verbindungen
US5733572A (en) *	1989-12-22	1998-03-31	Imarx Pharmaceutical Corp.	Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5709879A (en) *	1990-06-29	1998-01-20	Chiron Corporation	Vaccine compositions containing liposomes
US5324512A (en) *	1990-12-26	1994-06-28	The Population Council	[Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
US5387421A (en) *	1991-01-31	1995-02-07	Tsrl, Inc.	Multi stage drug delivery system
IL105325A (en) *	1992-04-16	1996-11-14	Minnesota Mining & Mfg	Immunogen/vaccine adjuvant composition
US5576016A (en) *	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
EP0705109B2 (en) *	1993-05-25	2004-01-02	American Cyanamid Company	Adjuvants for vaccines against respiratory syncytial virus
US5773011A (en) *	1993-09-27	1998-06-30	Gerbu Biotechnik Gmbh	Method of preparing a synergistic immunological adjuvant formulation
US5961970A (en) *	1993-10-29	1999-10-05	Pharmos Corporation	Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
FR2715843B1 (fr) *	1994-02-09	1996-04-12	Oreal	Compositions cosmétiques antisolaires, procédé de préparation et utilisation.
FR2716372B1 (fr) *	1994-02-18	1996-04-12	Oreal	Compositions cosmétiques antisolaires stables, fluides et/ou fluidifiables, procédé de préparation et utilisation.
DE69533693T2 (de) *	1994-02-24	2005-12-22	Novavax Inc.(n.d.Ges.d.Staates Delaware)	Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
FR2716622B1 (fr) *	1994-02-28	1996-04-12	Oreal	Compositions cosmétiques autobronzantes à base de dihydroxyacétone, procédé de préparation et utilisation.
ATE198152T1 (de) *	1994-09-30	2001-01-15	Takeda Chemical Industries Ltd	Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
US5858398A (en) *	1994-11-03	1999-01-12	Isomed Inc.	Microparticular pharmaceutical compositions
GB9422990D0 (en) *	1994-11-15	1995-01-04	Cortecs Ltd	Immunogenic compositions
IL117773A (en) *	1996-04-02	2000-10-31	Pharmos Ltd	Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
DE59710082D1 (de) *	1996-12-13	2003-06-18	Vesifact Ag Baar	Kosmetische Präparate in Form einer Nanodispersion
WO1998053799A2 (en) *	1997-05-28	1998-12-03	Jenner Biotherapies, Inc.	Immunogenic compositions
IS4518A (is) *	1997-07-09	1999-01-10	Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group	Nýtt lyfjaform fyrir bóluefni
HK1039072A1 (zh) *	1998-05-07	2002-04-12	科里克萨有限公司	佐剂组合物及其使用方法
DE69920380T2 (de) *	1998-12-18	2005-11-17	Shin-Etsu Chemical Co., Ltd.	Organopolysiloxan Öl-in-Wasser Emulsion und Verfahren zur Herstellung
US6288026B1 (en) *	1999-02-24	2001-09-11	Heinrich Exner	Process and composition for treating diseases with an oil-in-water emulsion
US6551598B2 (en) *	2000-01-21	2003-04-22	Merial	Vaccination against canine herpesvirosis and vaccines therefor

1999
- 1999-05-07 HK HK02100782.0A patent/HK1039072A1/zh unknown
- 1999-05-07 DE DE69937343T patent/DE69937343T2/de not_active Expired - Fee Related
- 1999-05-07 CN CNA200810008718XA patent/CN101219217A/zh active Pending
- 1999-05-07 BR BR9910269-2A patent/BR9910269A/pt not_active Application Discontinuation
- 1999-05-07 CN CN99807591A patent/CN1306438A/zh active Pending
- 1999-05-07 US US09/307,321 patent/US6630161B1/en not_active Expired - Fee Related
- 1999-05-07 CA CA002330610A patent/CA2330610A1/en not_active Abandoned
- 1999-05-07 AU AU39737/99A patent/AU755445B2/en not_active Ceased
- 1999-05-07 EP EP99922832A patent/EP1075276B1/en not_active Expired - Lifetime
- 1999-05-07 WO PCT/US1999/009978 patent/WO1999056776A2/en not_active Ceased
- 1999-05-07 PT PT99922832T patent/PT1075276E/pt unknown
- 1999-05-07 JP JP2000546800A patent/JP2002513773A/ja active Pending
- 1999-05-07 AT AT99922832T patent/ATE375803T1/de not_active IP Right Cessation
- 1999-05-07 ES ES99922832T patent/ES2296390T3/es not_active Expired - Lifetime
- 1999-05-07 KR KR1020007012438A patent/KR100682154B1/ko not_active Expired - Fee Related
- 1999-05-07 NZ NZ508013A patent/NZ508013A/en unknown
- 1999-05-07 DK DK99922832T patent/DK1075276T3/da active
- 1999-05-07 HU HU0101804A patent/HU225844B1/hu not_active IP Right Cessation
2000
- 2000-11-06 NO NO20005596A patent/NO20005596L/no not_active Application Discontinuation
- 2000-11-07 ZA ZA200006379A patent/ZA200006379B/en unknown
2003
- 2003-06-10 US US10/459,308 patent/US20030215497A1/en not_active Abandoned
2008
- 2008-01-10 CY CY20081100035T patent/CY1107265T1/el unknown

Also Published As

Publication number	Publication date
HUP0101804A2 (hu)	2001-11-28
BR9910269A (pt)	2001-01-09
ES2296390T3 (es)	2008-04-16
DE69937343D1 (de)	2007-11-29
CA2330610A1 (en)	1999-11-11
DE69937343T2 (de)	2008-07-24
KR20010043404A (ko)	2001-05-25
HU225844B1 (en)	2007-10-29
CY1107265T1 (el)	2012-11-21
EP1075276A2 (en)	2001-02-14
WO1999056776A3 (en)	2000-01-06
JP2002513773A (ja)	2002-05-14
US20030215497A1 (en)	2003-11-20
NO20005596L (no)	2001-01-05
EP1075276B1 (en)	2007-10-17
HK1039072A1 (zh)	2002-04-12
CN1306438A (zh)	2001-08-01
US6630161B1 (en)	2003-10-07
ZA200006379B (en)	2002-01-07
ATE375803T1 (de)	2007-11-15
HUP0101804A3 (en)	2003-11-28
WO1999056776A2 (en)	1999-11-11
KR100682154B1 (ko)	2007-02-12
PT1075276E (pt)	2008-01-22
NZ508013A (en)	2003-08-29
NO20005596D0 (no)	2000-11-06
CN101219217A (zh)	2008-07-16
AU3973799A (en)	1999-11-23
AU755445B2 (en)	2002-12-12

Publication	Publication Date	Title
DK1075276T3 (da)	2008-02-11	Adjuvanssammensætning og fremgangsmåder til dens anvendelse
AR025749A1 (es)	2002-12-11	Vacunas
MX9704097A (es)	1998-07-31	Induccion de respuestas de linfocitos t citotoxicos.
HRP20080235T3 (hr)	2008-07-31	Formulacija vakcine koja sadrži emulziju ulje-u-vodi
TR200002930T2 (tr)	2000-12-21	Kolaylaştırıcı kompozisyonlar
ES2168271T3 (es)	2002-06-16	Composiciones farmaceuticas que contienen ciclosporinas.
AR031273A1 (es)	2003-09-17	Cuaternarios de mono- y dialquilo en composiciones acondicionadoras para el cabello
AU578907B2 (en)	1988-11-10	Polyoxypropylene-polyoxyethylene block polymer based adjuvants
NO20002306L (no)	2000-06-16	FremgangsmÕte ved økning av absorpsjon og transport av lipid- oppløselige forbindelser ved Õ bruke strukturelle glycerider
EP0489153A4 (en)	1993-04-21	Vaccine compositions containing liposomes
ES2178997T3 (es)	2003-01-16	Composicion, particularmente cosmetica, que comprende una sapogenina.
ATE231003T1 (de)	2003-02-15	Tris enthaltende propofol-formulierung
BRPI0000126B8 (pt)	2022-05-10	composição de vacina, composição adjuvante e método de produção de uma composição de vacina
BRPI0413845A (pt)	2006-10-24	antioxidante que é baseado em ácido ascórbico, uso do antioxidante, e, preparação de gordura alimentìcia ou óleo alimentìcio
EP1453386A4 (en)	2005-12-21	FINISHED FOODS CONTAINING TRUCLYCERIDES RE-crystallized non-esterified PHYTOSTEROLS
DK0693547T3 (da)	2001-03-05	Antioxidantpræparat og fremgangsmåde til fremstilling deraf
ATE427123T1 (de)	2009-04-15	Orale pharmazeutische zubereitungen enthaltend cyclosporin
PT1096954E (pt)	2004-12-31	Composicoes de adjuvante e vacina contendo monofosforil-lipido a
EA200701743A1 (ru)	2008-02-28	Адъювантная композиция, содержащая фосфат алюминия и 3d-mpl
AR045996A1 (es)	2005-11-23	Formulaciones semi-solidas para la administracion oral de taxoides
RU2004101639A (ru)	2005-06-27	Антиоксиданты для полиамидов
DK1154792T3 (da)	2007-02-12	Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
CA2498891A1 (en)	2004-04-01	Thermolabile liposome with a controlled release temperature
ES2144648T3 (es)	2000-06-16	Prevencion de la hemolisis mediante agentes tensioactivos.
JPS57136511A (en)	1982-08-23	Preparation of ointment base containing silicone oil with high concentration